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INTRODUCTION:Gastrointestinal stromal tumours (GIST) account for only one percent of all gastrointesti-
nal malignancies.
PRESENTATION OF CASE: A 53 year old lady presented to the gastroenterology clinic with iron deﬁciency
anaemia. Oesophagogastroduodenoscopy (OGD) and computed tomography (CT) demonstrated a non-
obstructing 7 cm submucosal oesophageal lesion. An oesophagectomy was performed and subsequent
histology sections showedawell-circumscribed spindle cell tumourwithout anycellular atypia. Immuno-
histochemistry on the tumour was negative for S100 and positive for smooth muscle actin and desmin.
C-kit (CD117) showed focal positivity in some of the tumour cells and the overall features were of a
gastro-intestinal stromal tumour (GIST).
The patient has been fully compliant with the follow-up arrangements and is disease-free six years
after her original operation.
DISCUSSION: GISTs are mesenchymal tumours of the gastrointestinal (GI) tract that express the KIT
protein. The incidence rate for GIST is 15 cases to one million in the USA.
GISTs in the oesophagus are rare (5%) and their management is surrounded by some debate.
Once the diagnosis has been secured the patient should be evaluated for suitability for surgical resec-
tion.
Optimal surgical therapy should aim to achieve complete resection, if possible, without injury to
the pseudocapsule surrounding the tumour. Meticulous atraumatic surgical technique is necessary and
preoperative biopsies are best to be avoided as they might propagate seeding.
CONCLUSIONS:Oesophagectomywith clear resectionmargins should be thepreferredmethod for surgical
treatment combined with the use of novel TKI strategies.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gastrointestinal stromal tumours (GIST) account for only one
percent of all gastrointestinal malignancies. The oesophageal loca-
tion is considered to be a medical rarity and the gold standard
treatment is surgical resection of the tumour.
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2. Presentation of case
A 53 year old lady presented to our unit with iron deﬁ-
ciency anaemia. Oesophagogastroduodenoscopy demonstrated a
non-obstructing 7 cm submucosal oesophageal lesion which was
conﬁrmed by a computed tomography (CT) scan. No other signif-
icant pathology was visualised within the thorax or the abdomen.
On endoscopic ultrasound (EUS) a regular hypoechoic submucosal
lesion was visualised with the likely diagnosis of a leiomyoma, and
she was referred for a surgical treatment.
An oesophagectomy was performed via a vertical midline inci-
sion with bilateral subcostal extensions for the abdominal phase.
A postero-lateral thoracotomy was carried out for the thoracic
http://dx.doi.org/10.1016/j.ijscr.2015.02.023
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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phase. The stomach was tubularised and the oesophagectomy was
completed via the trans-thoracic route. An end to side oesophago-
gastrectomy was carried out. The patient made an unremarkable
post-operative recovery.
The histology sections showed awell-circumscribed spindle cell
tumour without any cellular atypia and there was no evidence of
increased mitotic activity to suggest malignant change.
Immunohistochemistry on the tumour was negative for S100,
epithelial markers and neuroendocrine markers.
The stains were tested positive for smooth muscle actin and
desmin indicating a smooth muscle origin. There was also focal
positivity for C-kit (CD117).
The overall features were consistent with a gastro-intestinal
stromal tumour (GIST).
The surveillance protocol consisted of two 3 monthly CT scans
followed by three 6monthly scans and annual scans thereafter. The
patient has been fully compliant with the follow-up arrangements
and is disease-free six years after her original operation.
3. Discussion
GISTs are deﬁned as pleomorphic mesenchymal tumours of
the gastrointestinal (GI) tract that express the KIT protein (CD
117-protooncogene) and often also CD34 (human progenitor cell
antigen) on immunohistochemistry [1,4].
The incidence rate for GIST is 15 cases to one million in the USA.
Similar incidence rates have been reported in studies from Europe
[1–3].
The stomach (50–60%) is most commonly affected followed
by the small intestine (30–40%). The colon and rectum may be
involved in5–10%of the cases.GISTs in theoesophagusare rare (5%)
and its management is surrounded by some debate (see Table 1)
[1–3,13,19,20].
The clinical presentation of GIST is very variable and dependant
on the size of the tumour and its localisation [1,2].
The symptoms are often unspeciﬁc. Dysphagia, obstruction
(10–30%), gastrointestinal bleeding (about 50%) and abdominal
pain (20–50%) are most common [2,3].
Twentypercent of tumours are incidental ﬁndings at endoscopy,
radiological imaging or surgery for other reasons [1,2].
In our case the OGD was requested for iron deﬁciency anaemia.
In the further evaluation of GIST, both radiological and endo-
scopic imaging techniques have a central role.
Generally, CT is the most useful method of assessing gastroin-
testinal stromal tumours and is considered to be the reference
diagnostic and staging modality. Alternatively magnetic resonance
imaging (MRI) can be considered (Fig. 1).
GISTs can be incidental ﬁndings at endoscopy performed for
other reasons [3,16].
EUS is a valuable adjunct to the diagnostic work-up of stromal
tumours. The main aim is to deﬁne the mass and its relationship
within the layers of the bowel wall [17].
The use of EUS with ﬁne-needle aspiration biopsy is a contro-
versial technique.
The general recommendation until now was against such a
practice, and it has been recommended to minimise the risk of
metastatic seeding by aiming for a R0 resection instead of taking
biopsies of the tumour. The latest guideline update of the NCCN
on the management of GIST (April 2010) states that biopsy is gen-
erally necessary when planning preoperative therapy for primary
GIST.
This probably reﬂects the fact that GISTs are often diagnosed
after image guided biopsy on patient with an abdominal mass of
unknown origin [15,16].
In our approach of making the diagnosis, we utilised EUS for
local staging but have refrained from taking biopsies in order to
prevent tumour rupture and seeding.
Once biopsies have been taken or the GIST has been resected a
deﬁnitive histological diagnosis can be made.
The histological classiﬁcation is according to the predominant
cell type, either spindle cell type (70–80%) or epithelioid type
(20–30%) [1–3] Fig. 2.
GISTs are KIT-expressing (tyrosine kinase receptor – CD117)
tumours. About 95% of the gastrointestinal stromal tumours, are
characterised by the CD117 antigen, which is considered to be a
marker with high sensitivity and speciﬁcity [2,3].
Pathohistology might also help with the risk stratiﬁcation of
patients although the biological behaviour of GISTS is difﬁcult to
predict.
An international consensus paper from 2002, suggested tumour
size and mitotic index as the two most important prognostic fea-
tures. Tumour necrosis, nuclear atypia and degree of staining for
CD117 do not reliably indicate the malignant potential of GISTs
[1,3,14].
Once the diagnosis has been secured the patient should be eval-
uated for suitability for surgical resection.
Even in theeraof imatinibmesylate, a thyrosinekinase inhibitor,
the preferred management of GIST is still surgical. In the absence
of metastatic disease, complete surgical excision is the treatment
of choice.
In order to provide optimal surgical management, the following
characteristics of GISTs should be considered:
First, GISTs often metastatise to the liver and peritoneum.
This is believed to be secondary to tumour rupture resulting in
mesenteric seeding which is common and can also lead to hep-
atic or mesenteric recurrence after apparently complete resection
[1,2].
Lymph node metastases on the other hand are rare, hence,
lymphadenectomy is unnecessary and should not be carried out
routinely.
Second, GISTs tend to grow towards the abdominal cavity, away
from the intestinal lumen.
Third, GISTs do not tend to invade adjacent structures. These
tumours tend to be discrete masses surrounded by a pseudocap-
sule.
Finally, GISTs are very fragile and rupture easily,making the risk
of peritoneal dissemination high. Especially, large GISTs can have a
necrotic centre, which makes the tumour prone to rupture during
operative manipulation.
Optimal surgical therapy should acknowledge the above charac-
teristics of GISTs and aim to achieve complete resection, if possible,
without injury to the pseudocapsule surrounding the tumour.
Meticulous atraumatic surgical technique is necessary, and preop-
erative biopsies are best to be avoided as they might propagate
seeding.
Successful R0 resection has been shown to be a good prognostic
indicator for the development of metastatic disease [2,3,19].
The last important aspect is the adequate symptoms control in
a palliative situation. In palliative therapy for bleeding or pain an
incomplete resection can be accepted [3,8,9,20].
The aim should be a maximum reduction of tumour mass,
including liver metastases.
Our casewas unique as theGISTwas localised to the oesophagus
and this brings a few challenges with it.
Most importantly the oesophagus lacks serosal covering, so
the risk of breakage is extremely high, and oesophageal resec-
tion is a technique that involves high morbidity and mortality
[19].
Blum et al. [20] analysed four cases, all in the distal oesophagus,
arguing for theoesophagectomyalternative to enucleation for large
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tumours and those close to the gastroesophageal junction (GEJ).
Small tumours (<2 cm), conﬁned to theoesophagealwall inpatients
at high risk, could be locally resected as long as negative resection
margins are obtained.
Enucleation is not a therapeutic option except for groups with
extensive experience.
Local resection of tumours <2 cm, provided that we can ensure
an R0 resection, or a standard resection in tumours >2 cm [13].
Where curative surgery is not feasible, or in patients who
develop recurrent metastatic disease, imatinib is now the ﬁrst line
treatment.
In 2010, the National Comprehensive Cancer Network (NCCN)
updated their clinical practice guidelines on the management of
patientswithGIST. As there is noweffective treatment for recurrent
ormetastaticGIST, theNCCN recommendsCT scans of the abdomen
and pelvis with IV contrast every 3–6 months during the ﬁrst 2–5
postoperative years and yearly thereafter.
The ESMO Guidelines Working Group approved clinical guide-
lines for diagnosis, treatment and follow-up of GIST in 2006 and
2008. The guidelines were updated recently in 2010.
The published guidelines partly diverge in their recommenda-
tions, and country speciﬁc health regulations may interfere with
their implementation.
4. Conclusion
The management of GIST has signiﬁcantly changed over the last
few decades. The imatinib and other inhibitors of tyrosine kinases
(TKI) have revolutionised the treatment of these mesenchymal
tumours. Oesophagectomy with clear resection margins should be
the preferredmethod for surgical treatment combinedwith the use
of novel TKI strategies.
Preoperative biopsies can not be recommended as they increase
the chances of mesenteric seeding.
Given the rarity of oesophageal disease establishing regional
networks and regional or national registries should provide sur-
geons with better information on GIST.
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Appendix A.
Table 1
Literature review of major case series (n>50) has shown that oesophageal GISTs are
rare.
Author Year n Oe F/U DFS/S Rc
Dematteo et al. [4] 2000 200 2 24 51/55 40%
Langer et al. [5] 2003 39 1 2.2 years 100/65 0/0 26%
Martin et al. [6] 2005 162 1 42 68/- 26%
Richter et al. [7] 2008 54 1 – 76/65 21%
Ahmed et al. [8] 2008 185 16 6.8 years -/100 -/55 11%
Das et al. [9] 2009 50 1 – 100/100 45/58 –
Monges et al. [10] 2010 591 4 Registry -/- -/-
Bülbül Dog˘usoy [11] 2012 1161 5 Registry -/- -/-
Siu et al. [12] 2013 93 3 58 64/69 16%
Rutkowski et al. [13] 2013 161 5 104 65/95 DFS/DSS 23%
(n – numbers of patients, Oe – number of oesophageal cases within cohort, F/U –
period, DFS – disease-free survival, S – survival, Rc – recurrence, DSS – disease-
speciﬁc survival).
Appendix B.
Fig. 1. Coronal views of the staging CT showing signiﬁcant thickening of the mid
oesophagus starting at the level of the aortic arch.
Fig. 2. Histopathologic image of the oesophageal gastrointestinal stromal tumor
(GIST). H & E stain.
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